medigraphic.com
Órgano Oficial de la Sociedad Mexicana de Angiología y Cirugía Vascular

2017, Number 1

<< Back Next >>

Rev Mex Angiol 2017; 45 (1)

Comparación de la enoxaparina vs. heparina no fraccionada en el postoperatorio inmediato de exploración vascular

Bizueto-Rosas H, Gómez-Calvo CD, Hernández-Rivera LF, López-Arce GS, Armenta-López R, Aburto-Pérez R, Hernández-Pérez NA

Language: Spanish
References: 32
Page: 23-32
PDF size: 161.24 Kb.


ABSTRACT

Objective. To identify the differences between the enoxaparin and unfractionated heparin, comparing episodes of rethrombosis and complications in the immediate postoperative period.
Background. The acute limb ischemia it’s a challenge for vascular surgeons, for the associated comorbidities and cardiovascular risk factors. Thrombosis and embolism are the most common causes (90%). The femoropopliteal segment is the most common site. Due to imminent risk of limb loss, early diagnosis and treatment is mandatory; thrombectomy or surgical embolectomy is the main procedure. For the post procedure anticoagulation is recommended the conventional heparin, continuing with coumarin. Fractionated heparin, can be used, however, there are no studies that have compared both heparins.
Material and methods. We performed a retrospective study of cases and controls by selecting the records with patients postoperated of femoral thromboembolectomy, assigning them into two groups: those treated with conventional heparin and enoxaparin, to identify the differences between both drugs and episodes of rethrombosis and complications in the immediate postoperative period. Statistical analysis: descriptive statistics, χ2 , Mann-Whitney U.
Results. Only the association between the type of anticoagulation and reoperation had statistical significance (P = 0.0468); the other variables, were not significant.
Conclusions. This study is not conclussive for the number of cases and the minimal difference between the variables. However, does not imply that it is not useful, therefore we can use one or the other.


REFERENCES

  1. Ouriel K. Acute arterial occlusion of the lower extremities. In: Ascher E, Veith FJ, Gloviczki P (Eds.). Haimovici’s Vascular Surgery 6th ed Oxford, Blackwell Publishing Ltd; 2012; 55: 703-09.

  2. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45(Suppl.): 5S-67S.

  3. Byrne J. Acute limb ischemia. Etiology and Natural History: Diagnosis and evaluation. In: Hallett JW Jr., Mills JL, Earnshaw J, Reekers JA, Rooke TW (Eds.). Comprehensive Vascular and Endovascular Surgery, 2nd Ed. Philadelphia, Mosby Elsevier; 2009; 13: 243-61.

  4. Enríquez-Vega ME, Cossio-Zazueta A, Flores-Escartín M. Diagnóstico y tratamiento de la enfermedad arterial periférica. Guía de práctica clínica. Instituto Mexicano del Seguro Social 2009. CENETEC. Disponible en: www. cenetec. salud. gob. mx/descargas/g p c / IMSS_007_08_EyR.pdf.

  5. Cantú-Brito C, Chiquete-Anaya E, Duarte-Vega M, Rubio- Guerra A, Herrera-Cornejo M, Nettel-García J. Estudio multicéntrico INDAGA. Índice tobillo-brazo anormal en población mexicana con riesgo vascular. Rev Med Inst Mex Seguro Soc 2011; 49(3): 239-46.

  6. Fogarty TJ, Cranley JJ, Krause RJ, Strasser ES, Hafner CD. A Method for extraction of arterial emboli and thrombi. Surg Gynecol Obstet 1963; 116: 241-44.

  7. Alonso-Coello P, Bellmunt S, McGorrian C, Anand SS, Guzmán R, Criqui MH, et al. Antithrombotic therapy in peripheral artery disease antithrombotic therapy and prevention of thrombosis. 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl. 2): 669S-690S.

  8. Johnson EA, Kirkwood TB, Stirling Y, Pérez-Requejo JL, Ingram GI, Bangham DR, et al. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 1976; 35(3): 586-91.

  9. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GE. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-83.

  10. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractioned heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996; 334(11): 677-81.

  11. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995; 332(20): 1374-6.

  12. Davoren A, Aster RH. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol 2006; 81: 36-44.

  13. Hutchison CA, Dasgupta I. National survey of heparininduced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant 2007; 22: 1680-4.

  14. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular- weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106: 2710-5.

  15. Hook KM, Abrams CS. Treatment options in heparin-induced trombocytopenia. Curr Opin Hematol 2010; 17: 424-31.

  16. Rajgopal R, Bear M, Butcher MK, Shaughnessy SG. The effects of heparin and low molecular weight heparins on bone. Thromb Res 2008; 122(3): 293-8.

  17. Handschin AE, Trentz OA, Hoerstrup SP, Kock HJ, Wanner GA, Trentz O. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 2005; 92: 177-83.

  18. Lai KN, Ho K, Cheung RC, Lit LC, Lee SK, Fung KS, et al. Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int J Artif Organs 2001; 24(7): 447-55.

  19. Benítez M, González Gómez I, González Carmelo I, Palma A, Cruz S, Rodríguez E, et al. Trombopenia inmune inducida por heparina en hemodiálisis a propósito de un caso. Revisión de la literatura. Nefrología 2007; 27: 756-60.

  20. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45-54.

  21. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmüller A, Juillard-Delsart D, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular weight heparins: a metaanalysis of randomized clinical trials. Thromb Haemost 2000; 83(1): 14-9.

  22. Galeote G, Moreno R, Sánchez-Recalde A, Jiménez-Valero S, Calvo L, Rivero F, et al. Eficacia y seguridad de la enoxaparina en la angioplastia primaria. Análisis comparativo con la heparina no fraccionada. Med Intensiva 2009; 33(1): 1-7.

  23. Monagle P, Chan AK, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Gottl U, et al. Antithrombotic therapy in neonates and children: Antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl. 2): 737S-801S.

  24. Kayssi A, Shaikh F, Roche-Nagle G, Brandao LR, Williams SA, Rubin BB. Management of acute limb ischemia in the pediatric population. J Vasc Surg 2014; 60(1): 106-10.

  25. Encke A, Breddin K. Comparacion entre la heparina de bajo peso molecular y la heparina no fraccionada. Rev Med de Costa Rica y Centroamérica 1994; 528: 115-22.

  26. Creager MA, Kaufman JA, Conte MS. Clinical practice. Acute limb ischemia. N Engl J Med 2012; 366(23): 2198- 206.

  27. Earnshaw JJ. Acute ischemia: Evaluation and decision making. In: Cronenwett JL, Johnston KW (Eds.). Rutherford’s Vascular Surgery 8th. Ed. Philadelphia: Elsevier Saunders; 2014, p. 2518-27.

  28. Salzman EW. Low molecular weight heparin: la small beautiful? N Engl J Med 1986; 315: 957-9.

  29. Gramse CA, Hingorani A, Ascher E. Postoperative anticoagulation in vascular surgery: part 1. A retrospective comparison of clinical outcomes for unfractionated heparin versus low-molecular-weight heparin. J Vasc Nurs 2001; 19(2): 42-51.

  30. Hingorani A, Gramse C, Ascher E. Anticoagulation with enoxaparin versus intravenous unfractionated heparin in postoperative vascular surgery patients. J Vasc Surg 2002; 36(2): 341-5.

  31. Manterola C, Pineda V. El valor de “p” y la “significación estadística”. Aspectos generales y su valor en la práctica clínica. Rev Chil Cir 2008; 60(1): 86-9.

  32. Bradford-Hill A. Ambiente y enfermedad: ¿asociación o causación? Bol Oficina Sanit Panam 1992; 113: 233-42.




2020     |     www.medigraphic.com